AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2026 Issue 1; Section X – New Technology
Intracochlear Administration of DB-OTO
In table XW0, Introduction of Anatomical Regions, substance value 3 DB-OTO via Intracochlear Infusion, and body part value E Ears, were added to approach value 3 Percutaneous, to capture the intracochlear infusion of DB-OTO when it is used to treat congenital hearing loss due to biallelic mutations in the otoferlin (OTOF) gene. DB-OTO delivers a working copy of the OTOF gene into the cochlea.Body Part Approach Device/Substance/Technology Qualifier E Ear(s) 3 Percutaneous 3 DB-OTO via Intracochlear Infusion B New Technology Group 11 ...
Subscribe or sign in to view the full article.
Article Overview
This article explains a coding update in ICD-10-PCS involving intracochlear administration of a gene therapy product for the ears. It is relevant for coding professionals working with inpatient procedure coding, hearing-loss-related care, and new-technology coding updates. The article provides a brief overview of the table change, the clinical context for the technology, and the affected procedure elements.
Why This Topic Matters
It helps readers understand a newly added procedure construct in ICD-10-PCS and how the update fits into coding for emerging therapies used in congenital hearing loss care.
What You Will Learn
- What procedure coding area is being updated
- How the article frames the clinical context for the therapy
- Which broad ICD-10-PCS table elements are affected by the update
- How the update relates to new technology coding
Who Should Read This
- Hospital inpatient coders
- Coding educators
- Revenue cycle staff
- Clinical documentation specialists
- Health information management professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com